Sangamo Therapeutics (SGMO)
(Real Time Quote from BATS)
$0.95 USD
-0.01 (-1.06%)
Updated Sep 23, 2024 12:50 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Sangamo Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -257.83 | -192.28 | -178.30 | -121.12 | -95.42 |
Depreciation/Amortization & Depletion | 109.35 | 19.32 | 20.48 | 12.54 | 4.90 |
Net Change from Assets/Liabilities | -164.03 | -82.32 | -101.90 | 252.59 | -73.01 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 87.68 | 31.65 | 26.46 | 25.87 | 19.13 |
Net Cash From Operating Activities | -224.84 | -223.63 | -233.25 | 169.88 | -144.40 |
Property & Equipment | -21.16 | -20.17 | -23.28 | -14.71 | -20.68 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 174.69 | 79.46 | 271.48 | -256.91 | -39.13 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 153.53 | 59.29 | 248.20 | -271.63 | -59.80 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 16.04 | 86.76 | 36.12 | 153.87 | 142.45 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.45 | -2.10 | -3.26 | -0.77 | -0.42 |
Net Cash from Financing Activities | 14.59 | 84.66 | 32.86 | 153.10 | 142.03 |
Effect of Exchange Rate Changes | 1.48 | 1.25 | -0.26 | -0.45 | 0.18 |
Net Change In Cash & Equivalents | -55.24 | -78.43 | 47.54 | 50.90 | -61.99 |
Cash at Beginning of Period | 101.94 | 180.37 | 132.83 | 81.93 | 143.92 |
Cash at End of Period | 46.70 | 101.94 | 180.37 | 132.83 | 81.93 |
Diluted Net EPS | -1.48 | -1.25 | -1.23 | -0.90 | -0.85 |
Fiscal Year End for Sangamo Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -85.22 | -49.09 | -257.83 | -197.54 | -93.37 |
Depreciation/Amortization & Depletion | 4.83 | 2.25 | 109.35 | 106.64 | 99.38 |
Net Change from Assets/Liabilities | -6.36 | -8.90 | -164.03 | -164.82 | -162.14 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.20 | 7.07 | 87.68 | 81.41 | 29.12 |
Net Cash From Operating Activities | -75.55 | -48.66 | -224.84 | -174.30 | -127.01 |
Property & Equipment | 0.00 | 0.00 | -21.16 | -18.48 | -15.74 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 35.97 | 35.84 | 174.69 | 134.31 | 93.94 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 35.97 | 35.84 | 153.53 | 115.82 | 78.20 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 22.07 | 22.52 | 16.04 | 15.83 | 15.82 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.48 | -0.40 | -1.45 | -1.40 | -1.30 |
Net Cash from Financing Activities | 21.59 | 22.12 | 14.59 | 14.42 | 14.52 |
Effect of Exchange Rate Changes | -0.93 | -0.67 | 1.48 | 0.13 | 0.68 |
Net Change In Cash & Equivalents | -18.92 | 8.63 | -55.24 | -43.93 | -33.61 |
Cash at Beginning of Period | 46.70 | 46.70 | 101.94 | 101.94 | 101.94 |
Cash at End of Period | 27.79 | 55.33 | 46.70 | 58.01 | 68.33 |
Diluted Net EPS | -0.18 | -0.27 | -0.35 | -0.59 | -0.66 |